Tuesday 18 March, 2008

Sanofi Aventis Sues Wockhardt Over Alfuzosin Patent

Sanofi-Aventis has filed suit against Wockhardt alleging that the Indian generics maker has infringed the Orange book listed patents for Sanofi prostate treatment Uroxatral (Alfuzosin) Extended release 10 mg tablets.
Alfuzosin hydrochloride is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. Alfuzosin was approved by the FDA for treatment of BPH in June 2003. The following are Orange book listed patents for (Alfuzosin) Extended release 10 mg tablets.
US4661491 (Expiry: JAN 18, 2011)- Method of use for the treatment of dysuria
US6149940 (Expiry: AUG 22, 2017)- Controlled release Tablet
Sanofi-Aventis has earlier sued 10 generic players like Actavis, Aurobindo, Barr Laboratories, Mylan, Par, Ranbaxy, Sun, Teva, Torrent and Apotexfor filing Para IV against orange book listed patents.

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker